No mechanism has been suggested for the presence of cardiac calcification in these mice, and whether DRP1 regulates calcification of other tissues, including the vasculature, is unknown. DRP1inhibition prevents rat vascular neointima formation in a balloon injury model, 12 suppresses lesion formation in diabetic apolipoprotein E (ApoE)-deficient mice, 13 and oxidized lowdensity lipoprotein induces DRP1-mediated mitochondrial fragmentation in human SMCs, 14 suggesting a possible role of DRP1 in vascular disease. Reduced mitochondrial fusion protein, mitofusin 2 that acts in an opposite function to that of DRP1-driven mitochondrial fission, is associated with atherosclerosis pathology in mice, 15, 16 rabbits, 17 and humans. 16 Overexpression of mitofusin 2 in atherosclerotic rabbits reduces lesion formation. 17 Taken together, these studies suggest a role of mitochondrial dynamics in atherosclerosis, a disease highly associated with calcification. Mutations in the dynamin 1-like gene encoding the DRP1 protein, including nonsense and dominant-negative mutations, have been reported in a small number of human patients. [18] [19] [20] [21] [22] [23] [24] Although these patients exhibited a wide range of pathologies, from normal early development to neuronal development defects, cardiovascular calcification has not been reported. As such, an involvement of DRP1 in human soft tissue calcification remains to be demonstrated. Therefore, we sought to examine whether DRP1 plays a role in human cardiovascular calcification and if its inhibition alters the calcification process.
Methods
Detailed methodology is included in the Online Data Supplement.
Results

DRP1 Localized to Calcified Areas of Human Carotid Arteries
To analyze DRP1 expression in human vascular disease conditions, we performed DRP1 immunostaining on human carotid atherosclerotic plaques (n=5). DRP1 immunoreactivity was high in tissues with calcification and more specifically around calcified areas ( Figure 1A ; Online Figure I ). DRP1 was observed in SMCs (HHF-35, α-smooth muscle actin) and some macrophages (CD68) in calcified human arteries ( Figure 1C and 1D). SMC mitochondrial area was enlarged in calcified compared with noncalcified regions of carotid artery tissue from patients undergoing endarterectomy (n=3), examined by electron microscopy ( Figure 1E ).
Increased DRP1 in Calcifying Human SMCs Associated With Mitochondrial Alterations
An established cell culture vascular calcification model 25 promotes the transition of SMCs to an osteoblast-like cell phenotype. α-Smooth muscle actin-positive (Online Figure  IIA) SMCs cultured under osteogenic conditions have increased activity of a key enzyme, tissue nonspecific alkaline phosphatase (TNAP), peaking at 2 weeks in culture, and develop a mineralized matrix at 3 weeks in culture. Osteogenic transition of primary human coronary artery SMCs increased (≈2-fold) DRP1 protein and mRNA ( Figure 2A ). To assess mitochondrial morphology in this model, mitochondria were labeled using MitoTracker Red, and live cell mitochondrial imaging analysis was performed with confocal microscopy. Human SMC mitochondria appeared to be more fragmented when cultured in osteogenic media (OM) compared with control media ( Figure 2B ). We confirmed these observations through quantifying mitochondrial aspect ratios, a measurement of the major mitochondrial axis to the minor axis. 
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Novelty and Significance
What Is Known?
• DRP1 (dynamin-related protein 1) regulates mitochondrial fission.
• Mitochondrial morphology changes during cell differentiation, and DRP1 has been shown to promote the differentiation of some cell types.
What New Information Does This Article Contribute?
• A novel association of DRP1 to cardiovascular calcification, with increased DRP1 observed in calcified human cardiovascular tissue and cells.
• DRP1 inhibition attenuated primary human smooth muscle cell and valve interstitial cell calcification, inhibited oxidative stress-mediated smooth muscle cell calcification, and prevented oxidative stress-mediated dysfunction in bone osteoblasts.
DRP1 is a promising therapeutic target for multiple diseases; however, the role of DRP1 in cardiovascular disease is not clearly defined. Here, we show that DRP1 associates with calcified human plaques and regulates osteogenic differentiation of cardiovascular cells. In addition, we report a novel function of DRP1 in regulating osteogenic differentiation-induced type 1 collagen secretion. These results support a role of mitochondrial dynamics in the opposite mineralization response of vascular and bone cells to oxidative stress and better define the role of DRP1 and mitochondrial dynamics in cardiovascular disease.
Mitochondrial aspect ratios were reduced in 2-week OM-cultured cells compared with control media conditions ( Figure 2B ). To test whether this change was because of DRP1 activity or protein content, the selective small molecule DRP1 inhibitor, mitochondrial division inhibitor 1 (Mdivi-1) was added at a concentration (50 μmol/L) previously reported to fully inhibit DRP1 activity in cells. 26 Mdivi-1 treatment attenuated OM-mediated mitochondrial aspect ratio reductions ( Figure 2B ) without altering OMmediated increases in DRP1 protein (Figure 2A ). To assess whether the changes in DRP1 and mitochondrial morphology we observed in human SMCs resulted in mitochondrial functional deficits, we used the tetramethylrhodamine ethyl ester reagent to measure mitochondrial membrane potential, a general marker of mitochondrial function. 27 Tetramethylrhodamine ethyl ester fluorescence was reduced in cells cultured in OM for 2 weeks, and this decrease was attenuated by DRP1 inhibition ( Figure 2C ).
Previous studies link DRP1 and PKC (protein kinase C), with PKCδ-inducing DRP1-driven fission activity in SMCs. 12, 28 Therefore, we examined PKC in relation to DRP1 changes under calcifying conditions. Immunohistochemistry showed increased PKCδ in the same calcified regions of human carotid arteries that stained for DRP1 ( Figure 1B ). Dexamethasone, a component of OM, increases fatty acid synthesis. 29 Fatty acids increase DRP1 30 and have been associated with PKC activation. 31 To test whether altered mitochondrial fission observed in OM conditions involved PKC, we measured PKC activity in cells cultured for 2 weeks in control media and OM. In human SMCs, PKC enzyme activity was elevated in OM with and without the addition of Mdivi-1 ( Figure 2D ).
DRP1 Inhibition Attenuated OM-Induced Cytoskeletal Changes, TNAP Activation, COL1A1 Secretion, and Human SMC Calcification
The OM-mediated alterations in mitochondrial alignment and aspect ratio that were attenuated by DRP1 inhibition, along with reports of cytoskeleton involvement in DRP1-mediated fission, 32 could indicate cytoskeletal alterations. 33 Because microtubule stability and PKC activity associate with SMC calcification suppression, 34 we assessed the tubulin and filamentous actin cytoskeleton of human SMCs undergoing osteogenic differentiation. Two-week OM treatment resulted in a modestly diffuse tubulin cytoskeleton and a more apparent actin cytoskeleton, a difference attenuated by Mdivi-1 ( Figure 2E ). Mdivi-1 increased α-TUBULIN acetylation, a modification associated with tubulin stability (Online Figure IIB) .
We next assessed whether the effects of Mdivi-1 treatment on cytoskeleton reflect the ability of DRP1 inhibition to block the transition of human SMCs to osteoblast-like calcifying SMCs. Intracellular calcium levels analyzed by Fluo-4 did not change in cells treated in OM for 2 weeks but slightly increased in both control media and OM conditions with the addition of Mdivi-1 ( Figure 3A ). DRP1 inhibition reduced OM-induced cellular TNAP mRNA, protein, and activity ( Figure 3B-3D ). OM reduced the calcification inhibitor and TNAP substrate, pyrophosphate, which was partially restored by DRP1 inhibition in human SMCs ( Figure 3E ). DRP1 inhibition attenuated OM-induced calcification, visualized by alizarin red and osteosense staining ( Figure 3F and 3J). To confirm the specificity of DRP1 inhibition in driving the anticalcification effects of Mdivi-1, we reduced DRP1 in human SMCs with small interfering RNA oligonucleotides (siRNA; DRP1 Western blot siRNA confirmation shown in Figure 2A ). In agreement with the inhibitor results, DRP1 siRNA attenuated the formation of a mineralized matrix in human SMCs cultured in OM for 3 weeks ( Figure 3F ). Mdivi-1 reduced the expression of the TNAP regulator, runt-related transcription factor 2, in human SMCs (Online Figure IIIA) . In addition, DRP1 inhibition attenuated oxidative stress-induced mineralization in human SMCs ( Figure 3G ) treated with a low concentration of hydrogen peroxide (H 2 O 2 ; 0.3 mmol/L). This concentration of H 2 O 2 induces SMC calcification without altering cell viability. 35, 36 Because DRP1 inhibition did not fully inhibit OM-induced TNAP activity, we looked at additional mechanistic pathways through which it may act to inhibit calcification. In our OM experimental conditions, DRP1 inhibition effects on SMC calcification were not mediated by the calcification inhibitors osteoprotegerin and matrix gla protein, endoplasmic reticulum (ER) stress, or oxidative stress without the addition of H 2 O 2 (Online Figures IIC, IID , and IIIB). Because calcifying vesicles use a collagen matrix to attach and mineralize, 37, 38 we assessed COL1A1 (type 1 collagen α 1) content. Mdivi-1 reduced human SMC type 1 collagen secretion from a 7.5-fold induction to a 2.5-fold induction in OM ( Figure 3H ) without altering COL1A1 mRNA ( Figure 3I ). Collagen staining using CNA (CNA35 collagen) probe 38 validated the increased collagen matrix produced in human OM-treated SMCs that was attenuated by DRP1 inhibition ( Figure 3J ).
DRP1 siRNA Reduced Human VIC Calcification
To analyze DRP1 in human valve calcification, we performed DRP1 immunostaining on calcified human aortic valves obtained from patients undergoing aortic valve replacement surgery (n=5). DRP1 immunoreactivity was detected in calcified valve tissue ( Figure 4A ). We next tested the role of DRP1 in human valve calcification using an established cell culture calcification condition, 39 in which primary human VICs were treated with OM containing inorganic phosphate and L-ascorbic acid for 3 weeks. DRP1 mRNA was significantly increased in OM ( Figure 4B ). DRP1 siRNA reduced human VIC calcification ( Figure 4C ). TNAP mRNA and activity were not induced during VIC calcification in our experiments, which was reflected by no changes in VIC pyrophosphate levels ( Figure 4D ). Similarly, runt-related transcription factor 2 mRNA was not strongly induced under these experimental conditions (Online Figure IIIC) . VIC COL1A1 secretion was increased by ≈1.5-fold in OM. This modest induction in VICs was not altered by DRP1 knockdown ( Figure 4E ). Examination of calcification-related transcription factors, Msh homeobox 2 and SOX9 (SOX gene family member 9), revealed no changes in Msh homeobox 2 expression, whereas SOX9 was elevated by DRP1 siRNA in VICs and by DRP1 inhibition in human SMCs (Online Figure IIIA and IIIC).
Mdivi-1 Reduced Human PBMC-Derived Osteoclastogenesis
We analyzed the in vitro effects of DRP1 inhibition on human vascular osteoclastogenesis through the use of primary human peripheral blood mononuclear cells (PBMCs). PBMCs were cultured in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor κ-B ligand to drive osteoclastogenesis. Twenty-five and 50 μmol/L Mdivi-1 reduced tartrate-resistant acid phosphatase (TRAP) activity in PBMCs by 68% and 72%, respectively (Online Figure IVA) . Fifty μmol/L Mdivi-1 disrupted large actin ring formation in human PBMCs while actin rings could be seen similar to that observed in untreated cells with 25 μmol/L Mdivi-1, but large multinucleated TRAP-positive cells were still less apparent (Online Figure IVA) . Given the similar dose effects observed in the PBMCs to reduce TRAP activity, we used 25 μmol/L Mdivi-1 to test the effects of DRP1 inhibition on human PBMC-derived osteoclast bone resorption. Time course analysis involving adding Mdivi-1 at the start of the 2-week osteoclast differentiation procedure, or starting at 4 or 7 days into the process, showed that Mdivi-1 alters human PBMC-derived osteoclasts through inhibition of differentiation but not through regulating the bone resorption activity of fully formed osteoclast-like cells (Online Figure IVB) . Immunohistochemistry was used to examine DRP1 in calcified low-density lipoprotein receptor-deficient, ApoEdeficient, and proprotein convertase subtilisin/kexin type 9 gain-of-function atherosclerosis mouse models; however, DRP1 was not enriched in calcified mouse plaque (Online Figure I) . In agreement, DRP1 protein and PKC activity were not increased in primary mouse SMCs cultured in OM (Online Figure VA and VB) , and DRP1 inhibition did not suppress mouse SMC mineralization in OM alone (Online Figure VC) . To test if the stress level required to elicit DRP1 changes was not reached in mouse SMC under the examined experimental conditions, we cultured mouse SMCs in OM with the addition of low levels of H 2 O 2 (0.3 mmol/L). H 2 O 2 increased oxidative stress (Online Figure VD) and DRP1 translocation to mitochondria ( Figure 5A ). Similar to human SMCs in OM, H 2 O 2 addition to mouse SMCs induced Tnap expression (Figure 5B) , the production of a calcified collagen-rich matrix ( Figure 5C and 5D) , and mitochondrial fragmentation ( Figure 5E ), all of which were attenuated by Mdivi-1 in addition to increasing Sox9 expression (Online Figure IIID) .
Drp1-deficiency is embryonic lethal in mice, therefore to further examine DRP1 inhibition in a mouse vascular calcification model, we used Drp1 heterozygous mice (Drp1 +/− ), which maintain ≈75% of wild-type DRP1 protein and are largely indistinguishable from wild-type mice. 40, 41 Mice were given a single tail vein injection of murine proprotein convertase subtilisin/kexin type 9 gain-of-function adeno-associated virus (which mimics low-density lipoprotein receptor-deficiency pathology in mice), fed an atherogenic diet for 20 weeks, and then analyzed in a similar manner to that which we and others have previously reported. [42] [43] [44] Drp1 +/− male mice (n=5) did not have significantly altered body weight, serum triglycerides, or total cholesterol compared with Drp1 +/+ male siblings ( Figure 6A ). Serum total proprotein convertase subtilisin/kexin type . DRP1 (dynamin-related protein 1) knockdown attenuated human valve interstitial cell calcification. A, Representative DRP1 immunohistochemistry image from calcified human aortic valve and adjacent section control (secondary antibody only; n=5 donors). B, DRP1 mRNA in primary human valve interstitial cells (VICs) treated in control media (CM) or osteogenic media (OM) with control or DRP1 small interfering RNA (siRNA) for 2 wk. C, Representative alizarin red staining and quantification from human VICs treated for 3 wk. D, Media pyrophosphate and (E) media COL1A1 (type 1 collagen α 1) ELISA from VICs treated for 2 wk. n=3 donors; *P<0.05, P**<0.01, ***P<0.001, ****P<0.0001; error bars indicate SD. ns indicates not significant.
(endogenous+gain-of-function) trended lower but was not significantly reduced in Drp1
+/− mice ( Figure 6A ). In addition, aortic root oil red O, MAC3 (macrophage), and TRAP activity staining was not altered in Drp1 +/− mice ( Figure 6B ). Picrosirius red stain visualized under polarized light (fibrillar collagen accumulation) trended lower but was not significantly altered in Drp1 +/− aortic roots ( Figure 6B ).
In agreement with our primary mouse SMCs in OM without the addition of H 2 O 2 data and the lack of change observed in the mouse vascular DRP1 immunohistochemistry, TNAP activity and vascular calcification measured by osteosense fluorescence reflectance imaging 45 in mouse aortas were not significantly different in Drp1 +/− mice under these experimental conditions (Figure 7 ). Given the connection between cardiovascular and bone calcification, 46 we examined bone density in Drp1 +/− mice. Microcomputed tomographic analysis of mouse femurs revealed no changes in cortical thickness, bone volume/trabecular volume ratio, trabecular thickness, trabecular number, or trabecular spacing ( Figure 8A ). Human osteoblast mitochondria appeared more fragmented with the addition of H 2 O 2 , a difference that was attenuated with Mdivi-1 ( Figure 8B ). In addition, Mdivi-1 suppressed human osteoblast mineralization dysfunction after H 2 O 2 treatment, analyzed by alizarin red staining ( Figure 8C ; Online Figure VI ).
Discussion
We report the following novel findings: (1) DRP1 associates with calcified human cardiovascular tissue and cells; (2) DRP1 inhibition attenuates primary human SMC and VIC Figure 6 . Drp1 +/− did not significantly alter atherosclerosis pathology in a PCSK9 (proprotein convertase subtilisin/kexin type 9) gain-of-function adeno-associated virus (AAV) mouse model. A, Body weight and serum triglycerides, total cholesterol, and PCSK9 from mice 20 wk post-PCSK9 gain-of-function AAV tail vein injection and maintained on an atherogenic diet. B, Representative images of aortic root oil red O, MAC3 (macrophage), tartrate-resistant acid phosphatase (TRAP) activity, and picrosirius red staining. n=5 C57Bl/6;129 male mice per group, with at least 2 sections per mouse analyzed; error bars indicate SD. Drp1 indicates dynamin-related protein 1; and ns, not significant. calcification; (3) Mdivi-1 reduces profibrotic COL1A1 secretion induced during human SMC osteogenic differentiation; and (4) Mdivi-1 attenuates oxidative stress-mediated human and mouse SMC calcification in addition to suppressing oxidative stress-mediated dysfunction in human osteoblasts. These results support our hypothesis that DRP1 promotes human cardiovascular calcification via regulating osteogenic differentiation. DRP1 associates with cell differentiation, with its inhibition blocking mouse myoblast 47 and Drosophila follicle cell 48 differentiation. In our calcification model, OM-reduced mitochondrial membrane potential and increased mitochondrial fragmentation could be attenuated by DRP1 inhibition, signifying a role of mitochondrial dynamics in osteogenic differentiation.
Along with its role in osteogenesis, TNAP is generally recognized as a marker of cell differentiation, and DRP1 inhibition reduces TNAP in pluripotent stem cells. 49 Because DRP1 inhibition reduced TNAP activity in OM-treated human SMCs and H 2 O 2 -treated mouse SMCs, TNAP reduction is a mechanistic component through which DRP1 regulates the reprogramming network that specifies SMC osteogenic differentiation. In contrast to the reduced TNAP activity we observed in human SMCs, DRP1 inhibition rescues oxidative stress-driven TNAP reductions in human bone osteoblast-like cells. 50 Similarly, we found that Mdivi-1 suppressed oxidative stress-mediated mineralization loss in primary human osteoblasts. No defects in long bones have been reported in patients with mutations in the dynamin 1-like gene encoding DRP1, and we did not observe changes in mouse bone density in Drp1 +/− femurs, suggesting cell type specificity in DRP1 regulation of mineralization. In agreement, the transcriptional program of calcifying SMCs and osteoblasts has been reported to not overlap, 51 suggesting cell type-specific mechanistic differences between bone and ectopic calcification, although cell heterogeneity may account for some expression pattern differences. Cell stress can produce cell type-specific calcification responses, exemplified by oxidative stress driving SMC but inhibiting osteoblast mineralization. 35 Mitofusin 2 but not Drp1 is elevated during mouse osteoblast differentiation, and mitofusin 2 knockdown reduces mitochondrial elongation and osteoblast differentiation. 52 Cells from humans that do not express any wild-type DRP1 are resistant to H 2 O 2 -induced mitochondrial fragmentation. 24 In agreement, we observed reduced mitochondrial aspect ratio and mineralization in human osteoblasts treated with H 2 O 2 , which was suppressed by Mdivi-1. Although H 2 O 2 similarly decreased SMC mitochondrial aspect ratio, it increased SMC calcification, which was attenuated by DRP1 inhibition. As such, calcifying SMCs and bone osteoblasts may have different metabolic needs that are better supported by fatty acid oxidation and mitochondrial respiration or glycolysis to supply energy, along with corresponding mitochondrial morphology changes during differentiation.
Because our VIC calcification condition did not involve TNAP induction, DRP1 inhibition attenuates cardiovascular cell calcification through additional mechanisms. Along with runt-related transcription factor 2, 36 the transcription factor SOX9 is associated with cardiovascular calcification. 53 Regulation of SOX9 by DRP1 requires further in-depth analysis beyond the scope of the present study. Our data indicate that DRP1 inhibition increased SOX9 expression in human SMCs, VICs, and H 2 O 2 -treated mouse SMCs. SOX9 inhibits valve calcification. 54 High variability of SOX9 has been reported in noncalcified vessels while calcified carotid lesions contain higher SOX9, 53 making the role of SOX9 in cardiovascular calcification unclear. However, increased SOX9 may act in a compensatory means to attenuate disease progression. 54 Our previous study associated macrophages with vascular calcification through the production of extracellular vesicles contributing to mineralization. 55 Whether macrophages play an additional role in calcification via mineral resorption by differentiating into osteoclast-like cells in the vasculature, however, remains unclear. Mdivi-1 suppressed PBMC osteoclastic differentiation but not mineral resorption in fully formed osteoclast in vitro, and we did not observe changes in MAC3 staining or TRAP activity in the aorta of heterozygous Drp1-deficient mice. Future studies may address the role of mitochondrial dynamics in monocytes and macrophages during in vivo calcification including conditions of enhanced oxidative stress because H 2 O 2 enhances osteoclastic differentiation. 56 Collagen is trafficked in vesicles from the ER 57, 58 before being secreted from cells, but the molecular mechanisms of how this is accomplished are not clear. Because the human SMC increase in OM-induced COL1A1 secretion exceeded the transcriptional increase, one intriguing possibility is that these cells may activate auxiliary mechanisms to increase the rate of collagen secretion involving DRP1. Alternatively, Mdivi-1 may have indirectly altered collagen transport resulting in less COL1A1 secretion in human SMCs undergoing osteogenic differentiation. In rat liver, DRP1 has been observed at the ER and in fractions containing secretory proteins. 59 In mice in which Drp1 is deleted in the liver, very-low-density lipoprotein secretion, serum cholesterol, and triglycerides significantly decrease on a high-fat diet without altering mitochondrial respiratory activity, liver ATP, or lipid content, 60 further supporting a role of DRP1 in cellular trafficking. In the present study, DRP1 inhibition in SMCs modestly increased intracellular calcium while blocking extracellular matrix mineralization. Intracellular calcium and calcium-binding proteins, such as annexins, have been associated with extracellular vesicles involved in the calcification process.
61 DRP1 interacts with annexin A6. 62 Annexin protein may maintain the architectural and functional features of ER exit sites. 63 Whether calcium regulation and annexins participate in DRP1 regulation of protein secretion and calcification requires further exploration. DRP1 is an ER resident protein in mouse β-cells, and dominant-negative Drp1 expression helps maintain β-cell ER structure under stressed conditions. 64 Together, these studies suggest a role of DRP1 in ER maintenance, which may explain our observation of decreased OM-induced COL1A1 secretion in Mdivi-1-treated human SMCs.
DRP1inhibition suppresses vascular disease pathology in diabetic ApoE-deficient mice, 13 and balloon 12 and wire injury 65 rodent models. In contrast, heterozygous Drp1-deficient mice did not have altered vascular pathology in a proprotein convertase subtilisin/kexin type 9 gain-of-function model, and DRP1 was not elevated in calcified plaque of the 2 most commonly used atherosclerosis mouse models, ApoE-deficient and low-density lipoprotein receptordeficient mice. We found that attenuation of mouse SMC calcification by Mdivi-1 required the addition of oxidative stress to the osteogenic differentiation condition. Because oxidative stress is elevated in diabetic and injury models, DRP1 inhibition may require the presence of certain stress levels to attenuate disease pathology in murine cardiovascular models. Oxidized low-density lipoprotein enhances SMC but suppresses osteoblast differentiation, increases cellular oxidative stress, 35 and induces DRP1-mediated mitochondrial fission in SMCs.
14 A recent study found that treating rat SMCs with the antioxidant flavonoid quercetin reduced DRP1 abundance and phosphate-induced calcification in an oxidative stress-dependent manner in vitro, along with suppressing calcification in adenine fed rats, 66 a model of chronic kidney disease. Although DRP1 abundance and direct inhibition of DRP1 remain to be examined in chronic kidney disease, mitochondrial diameter is increased in the kidneys of diabetic mice, and this increase is attenuated by dominant-negative DRP1. 67 The diabetes mellitus medication metformin suppresses diabetes mellitus-accelerated atherosclerosis in mice through DRP1 inhibition 13 and attenuates progression of arterial calcification in HIV-infected metabolic syndrome patients. 68 Given the connection between metabolic disease and cardiovascular calcification, conditions with enhanced oxidative stress, such as diabetes mellitus and chronic kidney disease, may provide clinically relevant in vivo models in which to further assess DRP1 inhibition effects on cardiovascular calcification. Humans heterozygous for DRP1 deletion or missense mutations do not have associated medical issues, 24 and Mdivi-1 does not produce organ toxicity in rats 69 ; however, several concerns need to be addressed before assessing DRP1 inhibition in a clinical setting, 70 particularly under prolonged treatment conditions. Despite high unmet clinical needs of cardiovascular calcification, the underlying mechanisms remain obscure. Our current study identifies DRP1 as a novel regulator of cellular fibrocalcific response, which may lead to further research supporting the development of new therapies to combat cardiovascular calcification, a global health burden.
